New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder

References

• World Health OrganizationThe Global Burden of Disease (2004 update)GenevaWorld Health Organization2008 Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdfAccessed November 20, 2013
   Google Scholar
• Rozensweig-LipsonSBeyerCEHughesZADifferentiating antidepressants of the future: efficacy and safetyPharmacol Ther2007113113414317010443
   PubMed Web of Science ®Google Scholar
• PapakostasGILimitations of contemporary antidepressants: tolerabilityJ Clin Psychiatry200768 Suppl 10111717900204
   PubMed Web of Science ®Google Scholar
• Bang-AndersenBRuhlandTJørgensenMDiscovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorderJ Med Chem20115493206322121486038
   PubMed Web of Science ®Google Scholar
• MørkAPehrsonLBrennumLTPharmacological effects of LU AA21004: a novel multimodal compound for the treatment of major depressive disorderJ Pharmacol Exp Ther2012340366667522171087
   PubMed Web of Science ®Google Scholar
• BétryCPehrsonAlEtiévantAEbertBSánchezCHadderjiNThe rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonismInt J Neuropsychopharmacol20131651115112723089374
   PubMed Web of Science ®Google Scholar
• PehrsonALCremersTBétryCLu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitter – a rat microdialysis and electrophysiology studyEur Neuropsychopharmacol201323213314522612991
   PubMed Web of Science ®Google Scholar
• HvenegaardMGBang-AndersenBPedersenHJørgensenMPüschlADalgaardLIdentification of the cytochrome P450 and other enzymes involed in the in vitro metabolism of a novel antidepressant, Lu AA21004Drug Metab Dispos20124071357136522496396
   PubMed Web of Science ®Google Scholar
• WangYMunsakaMHansonEThe effect of multiple-doses of fluconazole, or ketoconazole, on the single dose pharmacokinetic profile in healthy adult subjects (abstract)AAPS J201012S2T2381
   Google Scholar
• WangYWojtkowskiTRossGEffect of multiple doses of rifampicin on the single dose pharmacokinetics of Lu AA21004 [abstract]J Clin Pharmacol2010501082
   Web of Science ®Google Scholar
• ArebergJSøgaardBHøjerAMThe clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteersBasic Clin Pharmacol Toxicol2012111319820522448783
   PubMed Web of Science ®Google Scholar
• ChenGLeeRHøjerAMBuchbjergJKSerenkoMZhaoZPharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressantClin Drug Investig20133310727736
   PubMed Web of Science ®Google Scholar
• LiYKaabyKFSánchezCGulinelloMSerotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in ratsBehav Brain Res201325652052824016840
   PubMed Web of Science ®Google Scholar
• GuillouxJPMendez-DavidIPehrsonAAntidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in miceNeuropharmacology20137314715923721744
   PubMed Web of Science ®Google Scholar
• MørkAMontezinhoLPMillerSVortioxetine (LU 21004), a novel multimodal antidepressant, enhances memory in ratsPharmacol Biochem Behav2013105415023380522
   PubMed Web of Science ®Google Scholar
• du JardinKGJensenJBSanchezCPehrsonALVortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonismEur Neuropsychopharmacol Epub822013
   Web of Science ®Google Scholar
• BaldwinDSLoftHDragheimMA randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)Eur Neuropsychopharmacol201222748249122209361
   PubMed Web of Science ®Google Scholar
• MahableshwarkarARJacobsenPLChenYA randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorderCurr Med Res Opin201329321722623252878
   PubMed Web of Science ®Google Scholar
• JainRMahableshwarkarARJacobsenPLChenYThaseMEA randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorderInt J Neuropsychopharmacol201316231332122963932
   PubMed Web of Science ®Google Scholar
• AlvarezEPerezVDragheimMLoftHArtigasFA double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInt J Neuropsychopharmacol201215558960021767441
   PubMed Web of Science ®Google Scholar
• HenigsbergNMahableshwarkarARJacobsenPChenYThaseMEA randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorderJ Clin Psychiatry201273795395922901346
   PubMed Web of Science ®Google Scholar
• HäggströmLNielsenRZDragheimMRandomized double-blind study of vortioxetine versus agomelatine in adults with MDD after inadequate response to SSRI or SNRI treatmentEuropean Psychiatry201328Supp 1121920709
   PubMed Web of Science ®Google Scholar
• KatonaCHansenTOlsenCKA randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorderInt Clin Psychopharmacol201227421522322572889
   PubMed Web of Science ®Google Scholar
• BaldwinDSHansenTFloreaIVortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorderCurr Med Res Opin201228101717172422978748
   PubMed Web of Science ®Google Scholar
• BoulengerJ-PLoftHFloreaAA randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorderJ Psychopharmacol201226111408141622495621
   PubMed Web of Science ®Google Scholar
• TheunissenELStreetDHøjerAMVermeerenAvan OersARamaekersJGA randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognitionClin Pharmacol Ther201393649350123588319
   PubMed Web of Science ®Google Scholar